Skip to main content

Marc Miquel Moltó Abad

I am a biologist with experience in both clinical and preclinical research on lysosomal storage diseases. I am intrigued by the clinical complexity of these rare diseases. Their low incidence in the population, the limited knowledge about their pathophysiology and the limitations of their current treatment are important points that needs to be investigated. I am very interested in nanotechnology application as a tool to improve the treatment of these diseases as well as the life quality of these patients.

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Rare diseases
Cross-departmental services

Marc Miquel Moltó Abad

Institutions of which they are part

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Rare diseases
Cross-departmental services

I am a biologist with experience in both clinical and preclinical research on lysosomal storage diseases. I am intrigued by the clinical complexity of these rare diseases. Their low incidence in the population, the limited knowledge about their pathophysiology and the limitations of their current treatment are important points that needs to be investigated. I am very interested in nanotechnology application as a tool to improve the treatment of these diseases as well as the life quality of these patients.

I have experience in cell culture, in vitro and in vivo assays and the monitoring of clinical trials. Regarding basic research, I have participated in projects ranging from the field of cancer and telomere dysfunction, to projects about the study of nanoparticles application in order to improve the treatment of a rare metabolic disease (Fabry's disease).

In 2013 I got my Biology’s degree from the Universitat Autònoma de Barcelona and in 2015 I completed an official master's degree in Cytogenetics and Reproductive Biology at the same university where I was able to work on my cell culture skills (derivative publication in Oncotarget). Subsequently, I started to work as a research technician in the Rare Diseases Unit of the Vall d'Hebron University Hospital in Barcelona (2016-2019), where I collaborated in the coordination of research projects and clinical trials focused on a group of rare diseases called lysosomal storage diseases. Consequently, I am a co-author of different scientific publications (8), in specialized journals (Mol Genet Metab, J Clin Med, Orphanet J Rare Dis, J Bone Min Res).

In 2020, I began my journey as a predoctoral researcher in the Delivery and Targeting research group testing nanometric systems for the improvement of current treatment of Fabry disease. As a result, I am a co-author of a review paper (WIRES) and a scientific publication (J Extracel Ves).

Projects

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Ana Laura Cazurro Gutierrez, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala
Funding agency: Instituto de Salud Carlos III
Funding: 2494527.53
Reference: FORT23/00034
Duration: 01/01/2024 - 31/12/2027

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Ibane Abasolo Olaortua
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Mejora del tratamiento de las enfermedades de depósito lisosomal mediante vehículos nanométricos optimizados

IP: Ibane Abasolo Olaortua
Collaborators: Marc Miquel Moltó Abad, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 90306.55
Reference: SLT017/20/000181
Duration: 05/07/2021 - 31/12/2024

Vesículas extracelulares para el tratamiento de enfermeades lisosomales (Título provisional)

IP: Ibane Abasolo Olaortua
Collaborators: Laura García Latorre, Guillem Pintos Morell, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Zamira Vanessa Diaz Riascos
Funding agency: Instituto de Salud Carlos III
Funding: 153670
Reference: PI21/00936
Duration: 01/01/2022 - 31/12/2024

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

Alfonso Biarnes Suñe

Alfonso Biarnes Suñe

Reconstructive Surgery of the Locomotor System
Read more
Sara Martin Sastre

Sara Martin Sastre

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Martín Huerta García

Martín Huerta García

Read more
Gesualdina Busiello

Gesualdina Busiello

Predoctoral researcher
Neuroradiology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.